101 results about "Apoptosis Inhibition" patented technology

The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a cereblon, Von Hippel-Lindau ligase-binding moiety, Inhibitors of Apotosis Proteins, or mouse double-minute homolog 2 ligand, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation / inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

The invention relates to lactobacillus casei with immunoregulation, anti-inflammatory and anti-cervical cancer effects. The lactobacillus casei strain is named as LH23, the preservation number is CGMCC No.16656, and the strain can be used for regulating immunity, regulating M1 / M2 macrophage balance, increasing the number of Treg cells, improving the symptoms of mouse colitis, shortening the colonlength and apoptosis of intestinal epithelial cells, inhibiting excessive secretion of proinflammatory factors (TNF-alpha, IL-1beta and IL-6) and recovering the concentration of short-chain fatty acid(SCFAs) in the intestinal tract, can resist cervical cancer, inhibit proliferation of cervical cancer HeLa cells and acetylation modification of histone, cause apoptosis of the HeLa cells and inhibitexpression of human papilloma virus HPVE6 and E7 proteins. The strain is used for preparing fermented food for inhibiting inflammatory bowel diseases and cervical cancer, and has a very wide application prospect.

The present invention provides a dye lignin derivative containing nitrogen monoxide donor, and in particular relates to a compound which is produced by ester bond connection of dye lignin (Genistein, Gen) and nitric acid ester NO (nitrogen monoxide) donor. The precursor derivative of nitrogen monoxide donor dye lignin (NO-G) with connected ester bonds is produced through chemical reaction between dye lignin (genistein) and a corresponding nitric acid ester NO donor. The ester bonds are broken in the structure through biological changes and drift out of the original drug Gen and the NO donor; NO can be slowly released to coordinate with the Gen, and the dual coordinated anti-tumor mechanism demonstrates excellent effects on apoptosis inhibition for ovary cancer and apoptosis induction of the ovary cancer.

Provided is a pharmaceutical composition for preventing or treating neuronal diseases comprising, as an active ingredient, an exon 2-deleted AIMP2 variant (AIMP2-DX2) gene or a vector comprising the gene, and a method for treating neuronal diseases in animals other than humans, comprising administering the same to a subject in need of treatment. The pharmaceutical composition comprising, as an active ingredient, a AIMP2-DX2 gene or a vector comprising the gene has the effects of apoptosis inhibition, dyskinesia amelioration and oxidative stress inhibition and thus can be widely used for preventing and treating neuronal diseases such as Parkinson's disease and amyotrophic lateral sclerosis.

The present invention relates to the use of thioredoxin as, inter alia, a cell growth stimulator, as well as a screen for agents that are useful in reducing or preventing thioredoxin-associated apoptosis inhibition and agents that are useful in inhibiting thioredoxin stimulated cell growth.

The invention discloses application of a PD-L1 (Programmed Death-Ligand 1) spliceosome B as a marker for instructing administration of PD-L1 / PD1 immunotherapy. Expression of three different variable spliceosomes of PD-L1 can be observed in normal and mutant colorectal cancer cell systems, and eukaryotic expression vectors of the three spliceosomes are established and transfected into tumor cells without or with low PD-L1 expression. Tests further show that in co-culture of a tumor cell system with isoform b over-expression and immune cells, apoptosis of the immune cells is promoted, secretionof immune cell factors is inhibited, inhibition of immunoreactions in bodies of patients can be reminded, and clinical sample testing shows that isoform b of PD-L1 is a monitoring target of poor prognosis of tumor.

The invention discloses application of a substance for reducing USP1 expression in preparation of a medicine for treating children T-series acute lymphocytic leukemia. The invention discloses short hairpin RNA (Ribonucleic Acid) for forming a stem-loop structure. The short hairpin RNA is shRNA-1 or shRNA-2. The deubiquitination enzyme USP1 has the effects of inhibiting cell apoptosis and promotingcell proliferation in T-series acute lymphocytic leukemia cells, and the invention proves that inhibition of USP1 expression can promote apoptosis of tumor leukemia cells and inhibit proliferation ofleukemia cells. The invention provides a novel way for the treatment of T-series acute lymphocytic leukemia, and the deubiquitinase USP1 is expected to become a potential target for anti-leukemia treatment and has a very wide application prospect in the medical field.

The invention discloses a targeted human CD147 small molecule RNA interference sequence and the use thereof, which relate to small fragment RNA type medicines for restraining multiplication of cervical cancer cells, inducing cell apoptosis and enhancing chemical drug susceptibility of cells, and the use of the medicines. The interference sequence is as follows: SODN: CGUCAGAACACAUCAACGATT; and AODN: UCGUUGAUGUGUUCUGACGTT; the targeted human CD147 small molecule RNA interference sequence is used for multiplication of restraining human tumors, inducing apoptosis, restraining tumor invasion and metastasis and enhancing anti-tumor drug susceptibility.

There is provided a hair tonic comprising at least two of an inhibitor against 5α reductase type 2, an inhibitor against transforming growth factor β2, and an inhibitor against caspase-3; a method comprising screening for at least two of inhibition against 5α reductase type 2, inhibition against transforming growth factor β2, and inhibition against caspase-3, or comprising screening for inhibition against caspase-3 and then for apoptosis inhibition, and a hair loss inhibitor having the effect of inhibiting caspase-3, and a hair loss inhibitor having the effect of inhibiting caspase-3 and of inhibiting apoptosis.

The invention discloses small molecular polypeptide inhibiting MIRI and a vector and application thereof. A bioengineering technology is utilized, a section of sequence corresponding to polypeptide analogue is genetically recombined to a p3XFLAG-CMV eukaryotic expression vector; after it is proved that recombination is successful through enzyme digestion and sequential analysis, plasmid corresponding to the eukaryotic expression polypeptide analogue is transfected into myocardium cells, protein expression of polypeptide is proved through immunoblotting, and polypeptide recombination is achieved. It is proved through co-immunoprecipitation that the polypeptide analogue can promote interaction of PDCD4 and Nrf2, it is shown through cell biology experiments that the polypeptide analogue has the capacity of inhibiting myocardium cell apoptosis caused by myocardial ischemia and reperfusion injuries and the functions of resisting oxidative stress and apoptosis of the myocardium cells and inhibiting occurrence and development of MIRI.

Multifunctional compounds are provided, comprising two or more functional moieties selected from: (i) a moiety that imparts an iron chelator function; (ii) a moiety that imparts a neuroprotective function; (iii) a moiety that imparts combined antiapoptotic, neuroprotective and / or neurorestorative functions; (iv) a moiety that imparts brain MAO inhibition, preferably with little or no MAO inhibition in liver and small intestine; (v) a moiety that imparts cholinesterase inhibitory function; and (vi) a moiety that imparts an N-methyl-D-aspartic acid receptor (NMDAR) inhibition, and pharmaceutically acceptable salts and optical isomers thereof. The multifunctional compounds are useful in the treatment or prevention of diseases, disorders or conditions that can be prevented and / or treated by iron chelation therapy, and / or neuroprotection and / or neurorestoration, and / or apoptosis inhibition and / or MAO inhibition and / or cholinesterase inhibition and / or NMADR inhibition. The present invention encompasses compounds of the formulas I to VI.

The invention discloses siRNA interfering HIP-55 and anti-tumor application of siRNA interfering HIP-55. The nucleotide sequence of the siRNA is shown in a sequence III in a sequence table. The invention also provides a DNA molecule encoding the above siRNA. Experiments prove that HIP-55 is highly expressed in a tissue sample of a clinical lung cancer patient; and further researches show the following functions of the HIP-55: through interfering silent protein HIP-55 by RNA, tumor formation can be obviously inhibited, apoptosis is promoted, proliferation, cell cloning formation, cell migration and / or cell invasion are suppressed; therefore, siRNA interfering HIP-55 can be used for preparing products for preventing and / or treating tumors.

The invention belongs to the field of combination with the traditional Chinese medicine, obstetrics and gynecology and molecular pharmacology, and particularly relates to a traditional Chinese medicine composite containing angelica sinensis and having the function of treating endometriosis. The traditional Chinese medicine composite can restrain the expression level of the apoptosis inhibition factors Bc1-2 and Survivin in the endometriotic tissues of the endometriosis, and can promote the expression level of the apoptosis promoting factor Bax. The composite comprises the active ingredients in parts by weight: 1200 parts of angelica sinensis, 1000 parts of Chinese herbaceous peony, 1000 parts of cassia twig and 1000 parts of poria cocos. In the prescription, the angelica sinensis is warm in nature, and sweet and acrid in taste, can invigorate the circulation of blood, and has the function of removing stasis without disordering blood, thereby the angelica sinensis is a monarch medicament; the Chinese herbaceous peony is bitter in taste and bit in cold, not only can remove stasis by invigorating the circulation of blood, but also can remove stasis and durably dissipate hot by cooling the blood, thus the Chinese herbaceous peony is a ministerial medicament; the cassia twig is sweet, acrid and warm, and has the functions of warming blood vessel in which the blood and qi circulate, mediating Yin, activating Yang, and removing stasis; and the poria cocos is sweet and tasteless, and has the function of inducing diuresis with bland drug, thus the poria cocos is an adjuvant with the cassia twig to be good for removing defects. Various medicaments are jointly used, so that the traditional Chinese medicine composite has the functions of warming channel and dredging veins, removing stasis and generating freshness, and removing stasis and removing defects.